Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: Rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003)

International Journal of Stroke

Volumn 5, Issue 5, 2010, Pages 423-427

  Sandset, Else Charlotte ^a,b   Murray, Gordon ^c   Boysen, Gudrun ^d   Jatuzis, Dalius ^e   Kõrv, Janika ^f   Lüders, Stephan ^g   Richter, Przemyslaw S ^h   Roine, Risto O ⁱ   Terént, Andreas ^j   Thijs, Vincent ^k   Berge, Eivind ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e VILNIUS UNIVERSITY   (Lithuania)

^f TARTU UNIVERSITY HOSPITAL   (Estonia)

^g ST JOSEFS HOSPITAL   (Germany)

^h INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

ⁱ TURKU UNIVERSITY HOSPITAL   (Finland)

^j UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Acute stroke; Angiotensin receptors blockers; Antihypertensive therapy; Candesartan; Randomised controlled trial

Indexed keywords

ANGIOTENSIN RECEPTOR; CANDESARTAN; PLACEBO;

ACUTE DISEASE; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BARTHEL INDEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FOLLOW UP; FUNCTIONAL STATUS; HEALTH CARE COST; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; METHODOLOGY; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SCANDINAVIA; STROKE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; HUMANS; HYPERTENSION; RESEARCH DESIGN; SCANDINAVIA; STROKE; TETRAZOLES;

EID: 77956254236     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2010.00473.x     Document Type: Article

References (37)

1. Wallace JD, Levy LL. Blood pressure after stroke. JAMA 1981, 246:2177-80.
2. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002, 33:1315-20.
3. Bourestom NC. Predictors of long-term recovery in cerebrovascular disease. Arch Phys Med Rehabil 1967, 48:415-9.
4. Marquardsen J. The natural history of acute cerebrovascular disease: a retrospective study of 769 patients. Acta Neurol Scand 1969, 45((Suppl. 38)):11-171.
5. Marshall J, Shaw DA. The natural history of cerebrovascular disease. Br Med J 1959, 1:1614-7.
6. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 2004, 43:18-24.
7. Strandgaard S. The management of elevated blood pressure in acute stroke: preferential use of angiotensin II receptor antagonists? J Hypertens 2004, 22:877-8.
8. Geeganage C, Bath PMW. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews 2008, 4. Art. No.: CD000039. DOI, 10.1002/14651858.CD000039.pub2
9. Geeganage C, Bath PMW. Vasoactive drugs for acute stroke. Cochrane Database of Systematic Reviews 2010, 7. Art. No.: CD002839. DOI, 110.1002/14651858.CD002839.pub2
10. Bath P, Chalmers J, Powers W. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J Hypertens 2003, 21:665-72.
11. Tikhonoff V, Zhang H, Richart T, Staessen JA. Blood pressure as a prognostic factor after acute stroke. Lancet Neurol 2009, 8:938-48.
12. Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of Acute Ischaemic Stroke. Cerebrovasc Dis 1994, 4:204-10.
13. Slivka A. Effect of antihypertensive therapy on focal stroke in spontaneously hypertensive rats. Stroke 1991, 22:884-8.
14. Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W. Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J Cereb Blood Flow Metab 1988, 8:474-85.
15. Fagan SC, Kozak A, Hill WD. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 2006, 24:535-9.
16. Schrader J, Lüders S, Kulschewski A. The ACCESS Study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003, 34:1699-703.
17. Anderson CS, Huang Y, Wang JG. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008, 7:391-9.
18. Yusuf S, Diener HC, Sacco RL. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225-37.
19. Bath PM, Martin RH, Palesch Y. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis. Stroke 2009, 40:3541-6.
20. Inada Y, Wada T, Ojima M. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997, 19:1079-99.
21. Lindholm LH, Ibsen H, Dahlof B. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-10.
22. Berl T, Hunsicker LG, Lewis JB. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003, 138:542-9.
23. Stenman E, Edvinsson L. Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. Stroke 2004, 35:970-4.
24. Dahlof B, Devereux RB, Kjeldsen SE. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
25. Mogensen CE. The reno-protective role of AT(1)-receptor blockers. J Hum Hypertens 2002, 16((Suppl 3)):S52-8.
26. Redon J. Renal protection by antihypertensive drugs: insights from microalbuminuria studies. J Hypertens 1998, 16:2091-100.
27. Dahlof B, Devereux R, de FU. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997, 10:705-13.
28. Hansson L, Lithell H, Skoog I. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press 2000, 9:146-51.
29. Berge E, Barer D. Could stroke trials be missing important treatment effects? Cerebrovasc Dis 2002, 13:73-5.
30. McHugh G, Butcher I, Steyerberg EW. A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results of the IMPACT Project. Clinical Trials 2010, 7:44-57.
31. Murray GD, Barer D, Choi S. Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma 2005, 22:511-7.
32. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997, 349:1569-81.
33. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000, 355:1205-10.
34. Lees KR, Asplund K, Carolei A. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 2000, 355:1949-54.
35. Bath PM, Lindenstrom E, Boysen G. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001, 358:702-10.
36. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators 1. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998, 279:1265-72.
37. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.